seattle genetics, sgen, takeda, business, finance, stock, investing, trading
AeroVironment (AVAV) says it received an order valued at $4,862,674 under a contract with the Norwegian...
President and Chief Executive Officer of Seattle Genetics, commented: "The strong brentuximab vedotin data we reported during the fourth quarter of 2010 highlighted an important year for Seattle Genetics, and position the company
Seattle Genetics (NASDAQ:SGEN) reported a Q4 loss of $0.34 per share, narrower than consensus estimates for a loss of $0.38 per share. Revenues for the quarter fell 63% year-over-year to $8.1 million, missing consensus estimates o
You did not create any Kaltura items